Although GRM5 (coding for metabotropic glutamate receptor 5, mGluR5) is a promising target for treating cognitive deficits in schizophrenia and AD, its association with cognitive and brain phenotypes within this disorder has received little attention. Here, GRM5 is linked to Alzheimer disease.